Singh and colleagues describe a CRISPR-Cas9-based gene editing strategy to treat IPEX syndrome, a monogenic immune disorder caused by mutations in the FOXP3 gene. This evidence concerns the gene FOXP3 and immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome.